Iterum Therapeutics Announces CMO Transition and Consultant Role
TipRanks (Fri, 10-May 4:35 PM ET)
Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024
Globe Newswire (Mon, 6-May 8:00 AM ET)
Globe Newswire (Mon, 29-Apr 8:00 AM ET)
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Globe Newswire (Thu, 28-Mar 7:00 AM ET)
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
Globe Newswire (Thu, 21-Mar 4:30 PM ET)
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat
Globe Newswire (Fri, 15-Mar 8:00 AM ET)
Iterum Therapeutics Provides Business Update
Globe Newswire (Wed, 6-Mar 8:00 AM ET)
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Iterum Therapeutics PLC - Ordinary Share trades on the NASDAQ stock market under the symbol ITRM.
As of May 10, 2024, ITRM stock price declined to $1.55 with 106,546 million shares trading.
ITRM has a beta of 2.49, meaning it tends to be more sensitive to market movements. ITRM has a correlation of 0.08 to the broad based SPY ETF.
ITRM has a market cap of $20.82 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ITRM stock traded as high as $37.80 and as low as $.60.
ITRM has outperformed the market in the last year with a return of +34.8%, while the SPY ETF gained +27.8%. However, in the most recent history, ITRM shares have underperformed the stock market with its stock returning -4.3% in the last 3 month period and -7.2% for the last 2 week period, while SPY has returned +4.2% and +2.5%, respectively.
ITRM support price is $1.52 and resistance is $1.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ITRM stock will trade within this expected range on the day.